- Home
- EDD vs TNGX Comparison
EDD vs TNGX Comparison
Compare EDD & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDD
- TNGX
- Stock Information
- Founded
- EDD 2007
- TNGX 2014
- Country
- EDD United States
- TNGX United States
- Employees
- EDD N/A
- TNGX N/A
- Industry
- EDD Finance Companies
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EDD Finance
- TNGX Health Care
- Exchange
- EDD Nasdaq
- TNGX Nasdaq
- Market Cap
- EDD 307.8M
- TNGX 317.4M
- IPO Year
- EDD N/A
- TNGX N/A
- Fundamental
- Price
- EDD $4.82
- TNGX $1.76
- Analyst Decision
- EDD
- TNGX Strong Buy
- Analyst Count
- EDD 0
- TNGX 7
- Target Price
- EDD N/A
- TNGX $12.33
- AVG Volume (30 Days)
- EDD 254.3K
- TNGX 801.9K
- Earning Date
- EDD 01-01-0001
- TNGX 05-07-2025
- Dividend Yield
- EDD 7.52%
- TNGX N/A
- EPS Growth
- EDD N/A
- TNGX N/A
- EPS
- EDD N/A
- TNGX N/A
- Revenue
- EDD N/A
- TNGX $42,069,000.00
- Revenue This Year
- EDD N/A
- TNGX N/A
- Revenue Next Year
- EDD N/A
- TNGX N/A
- P/E Ratio
- EDD N/A
- TNGX N/A
- Revenue Growth
- EDD N/A
- TNGX 15.17
- 52 Week Low
- EDD $4.22
- TNGX $1.71
- 52 Week High
- EDD $4.95
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- EDD 55.15
- TNGX 33.97
- Support Level
- EDD $4.71
- TNGX $1.80
- Resistance Level
- EDD $4.91
- TNGX $2.04
- Average True Range (ATR)
- EDD 0.04
- TNGX 0.18
- MACD
- EDD 0.00
- TNGX 0.01
- Stochastic Oscillator
- EDD 52.50
- TNGX 20.19
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.